Chiesi Farmaceutici SpA has synthesized heterocyclic derivatives acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of acute lung injury, asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Tibet Haisco Pharmaceutical Co. Ltd. has disclosed integrin α4β7 (LPAM-1) and/or α4β1 (ITGA4; VLA-4) antagonists reported to be useful for the treatment of inflammatory disorders.
Yes, even a phase III protocol for a “failed” trial can constitute prior art, the U.S. Court of Appeals for the Federal Circuit told a lower court April 1 when it returned Janssen Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc.’s patent squabble for a do-over.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. has described EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Nectin Therapeutics Ltd. has divulged antibody-drug conjugates (ADCs) comprising a humanized monoclonal antibody targeting poliovirus receptors (PVR; CD155) linked to a cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.
Grafton Therapeutics Sarl has identified halogenated somatostatin analogues acting as somatostatin SST2 receptor and/or SST5 receptor agonists reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and neurodegeneration.
Researchers at Jinan Chengcheng Biotechnology Co. Ltd. and Shandong University have disclosed compounds acting as hypoxia-inducible factor 2-α (HIF-2α; EPAS1) activators and vaccine adjuvant reported to be useful for the treatment of stroke, hypertension, chronic kidney disease and more.
In what represents its first patenting, Anjo.ai Inc seeks protection of systems for remote monitoring, early detection and notification for life-threatening allergic anaphylactic reactions using wearable sensors and artificial intelligence. The system can recognize an allergic reaction even before the visible symptoms appear.
In what represents its first patenting, Austin, Texas-based Slipstream Solutions LLC is seeking protection for systems and methods for treating fluid stasis (e.g., edema) that employ an airstream to move static fluid to natural drainage areas such as lymph nodes or ducts.
RSS
